Predicting therapy response to mycophenolic acid using UGT1A9 genotyping: towards personalized medicine in atopic dermatitis

Predicting therapy response to mycophenolic acid using UGT1A9 genotyping: towards personalized medicine in atopic dermatitis

Atopic dermatitis (AD) is a very common chronic inflammatory skin disease requiring long-term treatment. Mycophenolic acid (MPA) is used off-label in treatment of patients with severe AD failing Cyclosporin A (CsA) treatment, however clinical efficacy is observed in only half of the AD patients. In...

Full description

Bibliographic Details
Main Authors: J. L. Thijs, B. A. M. Van Der Geest, J. Van Der Schaft, M. P. Van Den Broek, W. O. Van Seggelen, C. A. F. Bruijnzeel-Koomen, D. J. Hijnen, R. H. Van Schaik, M. S. De Bruin-Weller
Format: Article
Language:English
Published: Taylor & Francis Group 2017-04-01
Series:Journal of Dermatological Treatment
Subjects:
atopic dermatitis
mycophenolic acid
ugt1a9
pharmacogenomics
Online Access:http://dx.doi.org/10.1080/09546634.2016.1227420

Internet

http://dx.doi.org/10.1080/09546634.2016.1227420

Similar Items